MedPath
HSA Approval

PROCODIN SYRUP

SIN04075P

PROCODIN SYRUP

PROCODIN SYRUP

March 28, 1990

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05DA20

combinations

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

ICM PHARMA PTE. LTD.

Active Ingredients

CODEINE PHOSPHATE

9 mg/5 ml

Codeine

PROMETHAZINE HCl

3.6 mg/5 ml

Promethazine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.